New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareOvagen vs Follistatin

Ovagen vs Follistatin

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Ovagen
Anabolic & IGF
Follistatin
Summary
Ovagen is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, primarily targeting liver tissue. It supports hepatocyte function, liver cell regeneration, and protection against hepatic aging and disease. Ovagen is used in protocols for chronic liver disease, hepatoprotection, and metabolic liver conditions including fatty liver disease.
Follistatin is an endogenous glycoprotein that acts as a potent inhibitor of myostatin and activin, two proteins that limit muscle growth. By binding and neutralizing myostatin, follistatin removes the primary brake on skeletal muscle hypertrophy, enabling significant muscle growth beyond normal physiological limits. It is distinct from its isoforms Follistatin 315 and Follistatin 344 in tissue distribution and binding affinity.
Half-Life
Short (minutes); sustained gene-regulatory effects
~3–5 hours (endogenous form)
Admin Route
SubQ, Oral
IM, SubQ
Research
Typical Dose
10 mg per day
50–100 mcg per injection site
Frequency
Daily for 10–30 days
Every other day or 2–3x per week
Key Benefits
  • Hepatoprotective effects against toxic, viral, and metabolic liver damage
  • Promotes hepatocyte regeneration and liver tissue repair
  • May reduce liver fibrosis progression
  • Supports liver metabolic function and detoxification capacity
  • Anti-aging effects on hepatic tissue
  • Useful in NAFLD/MASH supportive protocols
  • Compatible with NAD+, glutathione, and BPC-157 in liver health stacks
  • Potent myostatin inhibition enabling supraphysiological muscle growth
  • Increases skeletal muscle mass and fiber size
  • May accelerate recovery from muscle injury
  • Potential benefits in muscular dystrophy and sarcopenia
  • Synergistic with IGF-1 and growth hormone in anabolic protocols
  • Animal studies show dramatic increases in muscle mass
  • Reduces muscle fibrosis in dystrophic models
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No clinically significant hepatotoxicity reported
  • Potential for excessive muscle growth if doses are not controlled
  • FSH suppression with implications for fertility in women
  • Theoretical risk of cardiac hypertrophy with prolonged high-dose use
  • Limited human safety data available
  • +1 more
Stacks With